

Relsys' ARGUS SAFETY™ is Now Available in a Hosted Version from Cato Research

Web access to leading safety system will benefit smaller pharmaceutical and biotechnology clients.

Irvine, CA and Research Triangle Park, NC – March 26, 2007 – Relsys International has announced a partnership with Cato Research (CATO), to provide a hosted version of Relsys' Argus Safety™ in the first quarter of 2007. Relsys International, the leading provider of software solutions for adverse event reporting, pharmacovigilance and risk management, will make the industry-leading Argus Safety™ solution available through CATO. CATO will provide the expertise to host, validate and support the application. The hosted version of Argus Safety™ is already in use by industry clients.

"We are both pleased and excited about our partnership with CATO to address the specific needs of organizations that currently are not ready to deploy their safety solution in-house. This initiative represents yet another way that Relsys is bringing value to both small and large pharmaceutical companies on a global level for their drug safety, pharmacovigilance and risk management needs," said Dave Bajaj, President and CEO of Relsys International. "CATO's progressive approach to addressing the needs of this thriving market allows Relsys' industry-leading Argus software to scale with the growth expected from these firms. We are confident that our products are highly beneficial to the industry."

Smaller clients with limited IT resources will benefit tremendously from this software as a service solution. Relsys' Argus Safety™ solution is a web-based application, making it easy to use for safety monitors, medical monitors, data entry, or anyone involved in the drug safety process. In the hosted offering, maintenance of a validated environment and administration of the system are the responsibility of CATO. As a consequence, on-going administration costs are also significantly reduced.

"We are committed to partnering with Relsys International in offering a trusted and innovative pharmacovigilance solution," said Dr. Allen Cato, CEO of CATO. "Our clients can be confident in knowing they are using state-of-the art software in a secure and stable environment, which is supported by a company with international resources helping the industry quickly and efficiently navigate the regulatory process for safety reporting. Our Pharmacovigilance team has the experience to oversee global safety reporting requirements for the lifecycle of a product and is capable of managing the entire process or assisting the sponsor in meeting their safety reporting requirements," added Lynda Sutton, Chief Regulatory Officer for CATO.

About Relsys International

Relsys International provides the industry-leading Argus suite, a complete systems solution for pharmacovigilance and risk management that help pharmaceutical, biotech and medical device companies improve drug safety and ensure ongoing compliance with global regulations. The company, founded in 1987, works in partnership with its customers to develop and deliver innovative solutions to long-term business needs, and to provide critical components to support its clients' corporate risk management strategies. Argus Safety™, the company's flagship product, is the world's best selling adverse event reporting software, and is used by more of the leading pharmaceutical companies than any other solution. Relsys is a privately held company, headquartered in Irvine, California. For more information, visit www.relsys.net, or call +1 949-453-1715.

About Cato Research Ltd.

Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and

medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients' products to market rapidly and cost-effectively. For more information, visit Cato Research's website at www.cato.com, or call +1 919-361-2286.